The Section 232 Pharmaceutical Tariff Proclamation: Board Governance and Supply Chain Strategy in an Era of Tariff-Driven Restructuring
On April 2, 2026, President Trump issued a proclamation imposing tariffs up to 100 percent on patented pharmaceuticals and active pharmaceutical ingredients (APIs) under Section 232 of the Trade Expansion Act of 1962. The tariffs take effect July 31, 2026 (for major...
The 100% Pharmaceutical Tariff: Three Paths, One Board Decision, 100 Days
President Trump’s April 2, 2026, Proclamation under Section 232 of the Trade Expansion Act of 1962 establishes a 100 percent ad valorem tariff on patented pharmaceutical products and their associated active pharmaceutical ingredients (APIs) imported into the...
The 100% Pharmaceutical Tariff: Three Paths, One Board Decision, 100 Days
President Trump’s April 2, 2026, Proclamation under Section 232 of the Trade Expansion Act of 1962 establishes a 100 percent ad valorem tariff on patented pharmaceutical products and their associated active pharmaceutical ingredients (APIs) imported into the...
The 100 Percent Tariff on Patented Drugs: What Pharma Boards Must Decide Before July 31
On April 2, 2026, President Trump signed a presidential proclamation imposing a 100 percent ad valorem tariff on imported patented pharmaceuticals and their active pharmaceutical ingredients under Section 232 of the Trade Expansion Act of 1962. For boards at...